evalu
effect
ribavirin
cytokin
product
recal
antigen
phastimul
pbmc
obtain
healthi
individu
materi
method
pbmc
challeng
tetanu
toxoid
ml
pha
absenc
presenc
ribavirin
differ
concentr
parallel
set
well
contain
pbmc
expos
medium
alon
use
neg
control
day
initi
cultur
ifn
tnfcontent
determin
supernat
pbmc
differ
individu
result
effect
ribavirin
cytokin
releas
human
pbmc
respons
pha
tt
show
great
variat
among
individu
signific
chang
observ
concentr
product
tnf
ifnand
pha
ttstimul
pbmc
ribavirin
inhibit
tnf
ifn
pha
ttstimul
pbmc
p
concentr
ribavirin
induc
increas
product
phastimul
pbmc
p
conclus
present
data
suggest
ribavirin
may
caus
divers
effect
immunoregulatori
cytokin
secret
chang
balanc
ribavirin
carboxamid
synthet
nucleosid
discov
consider
therapeut
potenti
treatment
viral
infect
human
ribavirin
inhibit
nucleic
acid
synthesi
replic
ribonucl
deoxyribonucl
acid
virus
interf
specif
inosin
dehydrogenas
cellular
enzym
requir
guanosin
biosynthesi
antivir
agent
inhibitori
activ
broadspectrum
viral
pathogen
includ
influenza
parainfluenza
virus
bunyavirus
respiratori
syncyti
viru
sever
acut
respiratori
syndrom
sar
viru
new
mutant
coronaviru
ribavirin
combin
alpha
interferon
consensu
treatment
chronic
hepat
c
remain
frequent
indic
drug
ribavirun
monotherapi
chronic
hepat
c
infect
normal
alaninoaminotransferas
alt
level
lead
biochem
respons
patient
minor
activ
serum
hcvrna
titer
recent
data
shown
treatment
combin
ribavirin
alpha
interferon
better
interferon
alon
sustain
virolog
respons
rate
moreov
combin
therapi
ribavirin
pegil
interferon
induc
sustain
virolog
respons
higher
proport
patient
although
mechan
drug
exert
respons
patient
chronic
hcv
infect
evalu
evid
ribavirin
like
immunomodulatori
antiinflammatori
effect
previou
studi
shown
ribavirin
immunosuppress
activ
reduc
lymphocyt
prolifer
mitogen
vitro
prolong
skin
allograft
surviv
rat
inhibit
mast
cell
secretori
process
carri
present
experi
evalu
vitro
effect
ribavirin
cytokin
product
recal
antigen
phastimul
human
peripher
blood
mononuclear
cell
pbmc
obtain
healthi
individu
overnight
fast
blood
sampl
collect
eight
healthi
adult
individu
studi
perform
accord
principl
declar
helsinki
approv
ethic
committe
institut
written
consent
obtain
volunt
compound
carboxamid
ribavirin
purchas
sigma
chemic
co
st
loui
usa
cell
cultur
pbmc
isol
heparin
blood
obtain
healthi
volunt
ficollhypaqu
gradient
centrifug
wash
pbmc
seed
roundbottom
well
cultur
cell
per
well
final
volum
rpmi
medium
supplement
antibiot
penicillin
uml
streptomycin
autolog
serum
lglutamin
pbmc
separ
challeng
phytohemaglutinin
pha
tetanu
toxoid
tt
recal
antigen
absenc
presenc
ribavirin
differ
concentr
parallel
set
well
contain
pbmc
expos
medium
alon
use
neg
control
ribavirin
differ
concentr
togeth
recal
antigen
screen
cytotox
activ
trypan
blue
exclus
test
cultur
maintain
humidifi
atmospher
supplement
co
day
initi
cultur
aliquot
supernat
collect
frozen
assay
interferon
ifn
tumor
necrosi
factor
tnf
content
recept
complet
differ
cultur
period
day
pha
day
recal
antigensstimul
pbmc
cell
harvest
ifn
tnfwere
determin
two
site
captur
elisa
use
two
monoclon
antibodi
ifn
tnfrespect
accord
instruct
given
manufactur
r
system
minneapoli
mn
pool
sampl
cultur
supernat
well
assay
measur
cytokin
content
amount
cytokin
estim
standard
curv
gener
plate
inclus
standard
concentr
respect
recombin
human
interleukin
result
express
mean
standard
deviat
sd
student
wilcoxon
match
pair
test
use
compar
continu
variabl
pvalu
lower
consid
statist
signific
evalu
effect
ribavirin
cytokin
product
human
pbmc
follow
polyclon
activ
g
pha
follow
addit
tetanu
toxoid
recal
antigen
cytokin
releas
ifn
tnf
measur
absenc
presenc
ribavirin
figur
effect
ribavirin
cytokin
releas
human
pbmc
respons
pha
tt
shown
great
variat
among
individu
signific
chang
observ
ribavirin
product
tnf
ifnand
pha
ttstimul
pbmc
ribavirin
significantli
inhibit
tnf
ifn
pha
ttstimul
pbmc
pha
tt
product
tnfand
ifnbi
pbmc
reduc
compar
baselin
p
phainduc
product
reduc
p
tt
stimul
reduc
p
ribavirin
induc
increas
product
phastimul
pbmc
p
detect
supernat
pbmc
stimul
pha
tt
absenc
presenc
ribavirin
studi
examin
vitro
effect
ribavirin
cytokin
product
human
peripher
blood
lymphocyt
expos
antigen
mitogen
stimul
found
ribavirin
induc
dosedepend
downregul
th
tnfand
ifn
th
cytokin
product
mitogen
antigenstimul
pbmc
show
experi
drug
capabl
inhibit
cytokin
secret
cultur
pbmc
dosedepend
fashion
howev
mark
interindividu
variat
observ
respons
drug
furthermor
found
effect
ribavirin
cytokin
secret
vari
basi
induc
stimulu
pha
tetanustoxoid
except
effect
ribavirin
given
combin
alpha
interferon
treatment
chronic
hepat
c
recent
report
howev
mechan
action
remain
unknown
sinc
drug
appear
exert
moder
transient
antivir
effect
even
though
benefici
effect
drug
viral
infect
attribut
broadspectrum
antivir
activ
ribavirin
may
also
exert
immunosuppres
effect
sinc
inhibit
prolifer
transform
cell
vitro
mechan
respons
hepatocellular
injuri
chronic
hepat
c
viru
infect
current
unclear
nevertheless
suggest
immun
mediat
liver
cell
damag
would
play
import
role
pathogenesi
diseas
well
cytokin
produc
cell
play
import
role
inhibit
viral
replic
caus
liver
injuri
order
explain
mechan
ribavirin
caus
normal
alt
level
patient
chronic
hepat
c
infect
hypothes
drug
may
act
immumodulatori
antiinflammatori
agent
result
show
ribavirin
high
concentr
may
induc
signific
increas
product
note
uniqu
featur
lymphocyt
activ
trigger
feedback
mechan
limit
prolifer
differenti
one
mechan
feedback
regul
prototyp
cell
growth
factor
function
paracrin
manner
stimul
clonal
expans
antigenstimul
lymphocyt
bystand
cell
earli
cell
respons
concentr
low
prolif
effect
may
domin
cytokin
accumul
may
function
termin
respons
therefor
high
level
enhanc
fasmedi
apoptosi
tcell
activ
feedback
control
mechan
activ
termin
tcell
immun
respons
agreement
observ
martin
et
al
report
high
concentr
ribavirin
markedli
increas
secret
suppress
ifnproduct
cultur
pbmc
chronic
hepat
c
patient
addit
found
ribavirin
inhibit
tnfsecret
proinflammatori
cytokin
effect
could
anoth
mechan
would
explain
alt
normal
patient
receiv
drug
ribavirin
nucleosid
analogu
broad
antivir
activ
vitro
inhibit
influenza
virus
parainfluenza
virus
respiratori
syncyti
viru
achiev
concentr
ribavirin
given
oral
bioavail
intraven
aerosol
adult
popul
peak
plasma
level
obtain
oral
dose
mg
intraven
administr
mg
may
produc
peak
plasma
level
aerosol
administr
ribavirin
found
plasma
level
although
concentr
respiratori
secret
higher
mean
serum
ribavirin
concentr
found
patient
chronic
hepat
c
treat
combin
therapi
serum
concentr
follow
oral
administr
mg
drug
report
nevertheless
shown
ribavirin
metabolit
could
select
concentr
retain
specif
cell
human
red
blood
cell
perhap
hepatocyt
moreov
ribavirin
found
significantli
higher
concentr
patient
sustain
respons
observ
effect
ribavirin
cytokin
product
doserel
sinc
higher
concentr
drug
induc
remark
effect
therefor
higher
concentr
ribavirin
may
capac
interfer
immun
respons
termin
cell
immun
mediat
damag
caus
persist
hcv
infect
conclus
present
studi
show
ribavirin
abl
induc
divers
effect
immunoregulatori
cytokin
secret
alter
balanc
chronic
hepat
c
drug
would
abl
reduc
cytokin
effect
immun
cell
via
abil
inhibit
prolifer
product
inflammatori
cytokin
